<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4666</article-id><article-id pub-id-type="doi">10.15789/2220-7619-CII-4666</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Changes in <italic>in vitro</italic> GM-CSF-exposured monocyte subset composition and phagocytic activity in children with infectious mononucleosis</article-title><trans-title-group xml:lang="ru"><trans-title>Изменение субпопуляционного состава и фагоцитарной активности моноцитов у детей с инфекционным мононуклеозом при воздействии GM-CSF <italic>in vitro</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Savchenko</surname><given-names>Andrei A.</given-names></name><name xml:lang="ru"><surname>Савченко</surname><given-names>Андрей Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Professor, Head of the Laboratory of Cellular-Molecular Physiology and Pathology</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, зав. лабораторией клеточно-молекулярной физиологии и патологии</p></bio><email>aasavchenko@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Martynova</surname><given-names>Galina Petrovna</given-names></name><name xml:lang="ru"><surname>Мартынова</surname><given-names>Галина Петровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Professor, Head of the Department of Pediatric Infectious Diseases</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, зав. кафедрой детских инфекционных болезней с курсом</p></bio><email>aasavchenko@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ikkes</surname><given-names>Lyubov A.</given-names></name><name xml:lang="ru"><surname>Иккес</surname><given-names>Любовь Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>assistant of the department of childhood infectious diseases with a PE-course of FSBEI of Higher Education</p></bio><bio xml:lang="ru"><p>ассистент кафедры детских инфекционных болезней с курсом ПО</p></bio><email>aasavchenko@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisov</surname><given-names>Alexandr G.</given-names></name><name xml:lang="ru"><surname>Борисов</surname><given-names>Александр Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Leading Researcher, Laboratory of Cellular-Molecular Physiology and Pathology</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, ведущий научный сотрудник лаборатории клеточно-молекулярной физиологии и патологии</p></bio><email>2410454@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtsev</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Кудрявцев</surname><given-names>Игорь Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Head of the Cell Immunology Laboratory, Department of Immunology, Assistant Professor Department of Immunology</p></bio><bio xml:lang="ru"><p>кандидат биологических наук, зав. лабораторией клеточной иммунологии отдела иммунологии, доцент кафедры иммунологии университета им. акад. И.П. Павлова</p>
<p> </p></bio><email>igorek1981@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Belenjuk</surname><given-names>Vasilij D.</given-names></name><name xml:lang="ru"><surname>Беленюк</surname><given-names>Василий Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Laboratory of Cellular-Molecular Physiology and Pathology</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории клеточно-молекулярной физиологии и патологии</p></bio><email>dyh.88@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal Research Center «Krasnoyarsk Science Center» of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North</institution></aff><aff><institution xml:lang="ru">ФГБНУ Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук», обособленное подразделение «НИИ медицинских проблем Севера»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Experimental Medicine</institution></aff><aff><institution xml:lang="ru">ФГБНУ НИИ экспериментальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Pavlov First Saint Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Far Eastern Federal University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВПО Дальневосточный федеральный университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-02-17" publication-format="electronic"><day>17</day><month>02</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-06-26" publication-format="electronic"><day>26</day><month>06</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>446</fpage><lpage>456</lpage><history><date date-type="received" iso-8601-date="2023-02-08"><day>08</day><month>02</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-02-12"><day>12</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Savchenko A.A., Martynova G.P., Ikkes L.A., Borisov A.G., Kudryavtsev I.V., Belenjuk V.D.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Савченко А.А., Мартынова Г.П., Иккес Л.А., Борисов А.Г., Кудрявцев И.В., Беленюк В.Д.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Savchenko A.A., Martynova G.P., Ikkes L.A., Borisov A.G., Kudryavtsev I.V., Belenjuk V.D.</copyright-holder><copyright-holder xml:lang="ru">Савченко А.А., Мартынова Г.П., Иккес Л.А., Борисов А.Г., Кудрявцев И.В., Беленюк В.Д.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/4666">https://iimmun.ru/iimm/article/view/4666</self-uri><abstract xml:lang="en"><p>The aim of the study was to investigate the features of changes in the monocytes subset composition and phagocytic activity in children with infectious mononucleosis (IM) exposed to granulocyte-macrophage colony-stimulating factor (GM-CSF) <italic>in</italic> <italic>vitro</italic>. We examined 84 children aged 3 to 11 years with Epstein–Barr virus (EBV) infection diagnosed by clinical signs, positive EBV DNA test in blood lymphocytes and ELISA data (EBV-VCAIgM (+), EBV-EA-DIgG (+)). The control group consisted of 40 apparently healthy age-matched children. Monocytes were obtained by the standard method on adhesion to plastic from mononuclear cells isolated from heparinized venous blood by density gradient centrifugation. The isolated monocytes were divided into two samples: control (without GM-CSF) and experimental (50 ng of GM-CSF per 1 ml of cell suspension). The monocyte subset composition and phagocytic activity in both samples were measured by flow cytometry after 1-hour incubation at 37°C in a CO<sub>2</sub>-incubator. It was found that in children with progressing IM, the blood monocyte subpopulation composition changes and their phagocytic activity is impaired. It was found that the subset composition and phagocytic activity of the blood monocytes changed in children during development of IM. Changes in the subset composition of monocytes in acute IM did not depend on the age group of children (3–6 and 7–11 years) and were characterized by increased number of pro-inflammatory (intermediate) monocytes and decreased level of anti-inflammatory (non-classical) monocytes. Features of altered monocyte phagocytic activity in children with IM depended on age. The phagocytic activity of all three monocyte subsets was reduced in children with IM 3–6 years old while children with IM 7–11 years old had reduced phagocytic activity only in intermediate and non-classical monocytes. The effect of GM-CSF <italic>in</italic> <italic>vitro</italic> on monocytes in patients with IM, regardless of the age of children, led to significantly increased level of anti-inflammatory monocytes while the phagocytic activity of cells changed less. An increase in the phagocytic number for classical monocytes after incubation with GM-CSF <italic>in</italic> <italic>vitro</italic> was noted in children with IM at the age of 3–6 years while the phagocytic index of this fraction of monocytes remained unchanged. The level of the phagocytic index increased only in classical monocytes of children with IM aged 7–11 years. The presented results determine the scientific and clinical value of studying the mechanisms of the effect of GM-CSF on cells of the immune system and prove that this cytokine can be used in a new immunotherapeutic strategy for the treatment of IM.</p></abstract><trans-abstract xml:lang="ru"><p>Целью исследования явилось изучение особенностей изменения субпопуляционного состава моноцитов и их фагоцитарной активности у детей с инфекционным мононуклеозом (ИМ) при воздействии гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF) <italic>in</italic> <italic>vitro</italic>. Обследовано 84 ребенка в возрасте от 3 до 11 лет с инфекцией вирусом Эпштейна–Барр (ВЭБ). Диагноз ВЭБ-инфекции ставился на основе клинических признаков ИМ, положительного теста на ДНК ВЭБ в лимфоцитах крови и результатов ИФА-тестов (ВЭБ-VCAIgM (+), ВЭБ-EA-DIgG (+)). Контрольную группу составили 40 практически здоровых детей аналогичного возрастного диапазона. Моноциты получали стандартным методом адгезии к пластику из мононуклеарных клеток, выделенных из гепаринизированной венозной крови центрифугированием в градиенте плотности. Выделенные моноциты разделяли на две пробы: контрольная (без GM-CSF) и опытная (50 нг GM-CSF на 1 мл клеточной суспензии). Определение субпопуляционного состава и фагоцитарной активности моноцитов в обеих пробах осуществляли методами проточной цитометрии после инкубации в течение 1 часа при температуре 37°С в CO<sub>2</sub>-инкубаторе. Обнаружено, что у детей на фоне развития ИМ меняется субпопуляционный состав моноцитов в крови и нарушается их фагоцитарная активность. Изменения субпопуляционного состава моноцитов на фоне острого ИМ не зависели от возрастной группы детей (3–6 и 7–11 лет), характеризовались повышением количества провоспалительных (промежуточных) моноцитов и снижением содержания противовоспалительных (неклассических) моноцитов. Особенности нарушения фагоцитарной активности моноцитов у детей с ИМ зависели от возраста. У больных 3–6 лет снижена фагоцитарная активность всех субпопуляций моноцитов, тогда как у детей с ИМ 7–11 лет понижена фагоцитарная активность промежуточных и неклассических моноцитов. При воздействии GM-CSF <italic>in</italic> <italic>vitro</italic> на моноциты у больных ИМ независимо от возраста значительно повышается уровень противовоспалительных моноцитов, в то время как фагоцитарная активность клеток меняется слабее. У детей 3–6 лет после инкубации с GM-CSF повышается фагоцитарной число для классических моноцитов, тогда как фагоцитарный индекс данной фракции моноцитов остается без изменений. У больных ИМ 7–11 лет также только у классических моноцитов повышается уровень фагоцитарного индекса. Приведенные результаты определяют научную и клиническую ценность изучения механизмов влияния GM-CSF на клетки иммунной системы и доказывают, что данный цитокин может быть использован в новой иммунотерапевтической стратегии лечения ИМ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>infectious mononucleosis</kwd><kwd>age of children</kwd><kwd>monocytes</kwd><kwd>subpopulations</kwd><kwd>phagocytic activity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>инфекционный мононуклеоз</kwd><kwd>возраст детей</kwd><kwd>моноциты</kwd><kwd>субпопуляции</kwd><kwd>фагоцитарная активность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Козлов В.А., Тихонова Е.П., Савченко А.А., Кудрявцев И.В., Андронова Н.В., Анисимова Е.Н., Головкин А.С., Демина Д.В., Здзитовецкий Д.Э., Калинина Ю.С., Каспаров Э.В., Козлов И.Г., Корсунский И.А., Кудлай Д.А., Кузьмина Т.Ю., Миноранская НАУЧНЫЙ СОТРУДНИК, Продеус А.П., Старикова Э.А., Черданцев Д.В., Чесноков А.Б., Шестерня П.А., Борисов А.Г. Клиническая имунология. Практическое пособие для инфекционистов. Красноярск: Поликор, 2021. 563 с. [Kozlov V.A., Tikhonova E.P., Savchenko A.A., Kudryavtsev I.V., Andronova N.V., Anisimova E.N., Golovkin A.S., Demina D.V., Zdzitovetsky D.E., Kalinina Y.S., Kasparov E.V., Kozlov I.G., Korsunsky I.A., Kudlay D.A., Kuzmina T.Yu., Minoranskaya N.S., Prodeus A.P., Starikova E.A., Cherdantsev D.V., Chesnokov A.B., Gear P.A., Borisov A.G. Clinical immunology. A practical guide for infectious diseases. Krasnoyarsk: Polikor, 2021, 563 p. (In Russ.)]</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кудрявцев И.В., Субботовская А.И. Опыт измерения параметров иммунного статуса с использованием шести-цветного цитофлуоримерического анализа // Медицинская иммунология. 2015. Т. 17, № 1. С. 19–26. [Kudryavtsev I.V., Subbotovskaya A.I. Application of six-color flow cytometric analysis for immune profile monitoring. Meditsinskaya immunologiya = Medical Immunology (Russia), 2015, vol. 17, no. 1, pp. 19–26. (In Russ.)] doi: 10.15789/1563-0625-2015-1-19-26</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Куликова М.М., Соломай Т.В., Семененко Т.А. Клинико-лабораторные особенности первичной острой и реактивации хронической Эпштейна–Барр вирусной инфекции у детей (систематический обзор и метаанализ) // Детские инфекции. 2022. Т. 21, № 1. С. 49–55. [Kulikova M.M., Solomay T.V., Semenenko T.A. Clinical and laboratory differences between primary acute and reactivation of chronic Epstein–Barr viral infection in children (systematic review and meta-analysis). Detskie infektsii = Children Infections, 2022, vol. 21, no. 1, pp. 49–55. (In Russ.)] doi: 10.22627/2072-8107-2022-21-1-49-55</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Савченко А.А., Гвоздев И.И., Борисов А.Г., Черданцев Д.В., Первова О.В., Кудрявцев И.В., Мошев А.В. Особенности фагоцитарной активности и состояния респираторного взрыва нейтрофилов крови у больных распространенным гнойным перитонитом в динамике послеоперационного периода // Инфекция и иммунитет. 2017. Т. 7, № 1. С. 51–60. [Savchenko A.A., Gvozdev I.I., Borisov A.G., Cherdancev D.V., Pervova O.V., Kudryavcev I.V., Moshev A.V. Phagocytic activity and blood neutrophils respiratory burst state features amongst widespread purulent peritonitis patients in the postoperative period dynamics. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2017, vol. 7, no. 1, pp. 51–60. (In Russ.)] doi: 10.15789/2220-7619-2017-1-51-60</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Савченко А.А., Борисов А.Г., Кудрявцев И.В., Мошев А.В. Зависимость фенотипа дендритных клеток от содержания провоспалительных моноцитов крови у больных раком почки // Медицинская иммунология. 2019. Т. 21, № 4. С. 689–702. [Savchenko A.A., Borisov A.G., Kudryavtsev I.V., Moshev A.V. Dependence of the phenotype of dendritic cells on the content of proinflammatory blood monocytes in patients with kidney cancer. Meditsinskaya immunologiya = Medical Immunology (Russia), 2019, vol. 21, no. 4, pp. 689–702. (In Russ.)] doi: 10.15789/1563-0625-2019-4-689-702</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Соломай Т.В., Симонова Е.Г., Семененко Т.А. Научное обоснование создания и перспективы развития системы эпидемиологического надзора за инфекцией, вызванной вирусом Эпштейна–Барр // Эпидемиология и вакцинопрофилактика. 2022. Т. 21, № 1. С. 21–31. [Solomay T.V., Simonova E.G., Semenenko T.A. Scientific Substantiation of the Creation and Prospects for the Development of an Epidemiological Surveillance System for Infection Caused by the Epstein–Barr Virus. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2022, vol. 21, no. 1, pp. 21–31. (In Russ.)] doi: 10.31631/2073-3046-2022-21-1-21-31</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Черенова Л.П., Мирекина Е.В., Лисина О.А., Иргазиева Г.К. Дифференциальная диагностика кори и инфекционного мононуклеоза // Инфекционные болезни: новости, мнения, обучение. 2022. Т. 11, № 1. С. 64–68. [Cherenova L.P., Merekina E.V., Lisina O.A., Irgazieva G.K. Differential diagnosis of measles and infectious mononucleosis. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training, 2022, vol. 11, no. 1, pp. 64–68. (In Russ.)] doi: 10.33029/2305-3496-2022-11-1-64-68</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Шульженко А.Е., Щубелко Р.В., Зуйкова И.Н. Герпесвирусные инфекции: современный взгляд на проблему. М.: ГЭОТАР-Медиа, 2022. 344 с. [Shulzhenko A.E., Shchubelko R.V., Zuikova I.N. Herpesvirus infections: a modern view of the problem. Moscow: GEOTAR-Media, 2022. 344 p. (In Russ.)]</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Achuthan A.A., Lee K.M.C., Hamilton J.A. Targeting GM-CSF in inflammatory and autoimmune disorders. Semin. Immunol., 2021, vol. 54: 101523. doi: 10.1016/j.smim. 2021.101523</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Albanese M., Tagawa T., Hammerschmidt W. Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host. Front. Microbiol. 2022, vol. 13: 955603. doi: 10.3389/fmicb.2022. 955603</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Alkhani A., Levy C.S., Tsui M., Rosenberg K.A., Polovina K., Mattis A.N., Mack M., Van Dyken S., Wang B.M., Maher J.J., Nijagal A. Ly6cLo non-classical monocytes promote resolution of rhesus rotavirus-mediated perinatal hepatic inflammation. Sci. Rep., 2020, vol. 10, no. 1: 7165. doi: 10.1038/s41598-020-64158-2</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Barman P.K., Shin J.E., Lewis S.A., Kang S., Wu D., Wang Y., Yang X., Nagarkatti P.S., Nagarkatti M., Messaoudi I., Benayoun B.A., Goodridge H.S. Production of MHCII-expressing classical monocytes increases during aging in mice and humans. Aging Cell, 2022, vol. 21, no. 10, pp. 13701. doi: 10.1111/acel.13701</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chilunda V., Martinez-Aguado P., Xia L.C., Cheney L., Murphy A., Veksler V., Ruiz V., Calderon T.M., Berman J.W. Transcriptional changes in CD16+ monocytes may contribute to the pathogenesis of COVID-19. Front. Immunol., 2021, vol. 24, no. 12, pp. 665773. doi: 10.3389/fimmu. 2021.665773</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Coillard A., Segura E. In vivo differentiation of human monocytes. Front. Immunol., 2019, vol. 13, no. 10, pp. 1907. doi: 10.3389/fimmu. 2019.01907</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Congy-Jolivet N., Cenac C., Dellacasagrande J., Puissant-Lubrano B., Apoil P.A., Guedj K., Abbas F., Laffont S., Sourdet S., Guyonnet S., Nourhashemi F., Guéry J.C., Blancher A. Monocytes are the main source of STING-mediated IFN- production. EBioMedicine, 2022, vol. 80: 104047. doi: 10.1016/j.ebiom. 2022.104047</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Falck-Jones S., Österberg B., Smed-Sörensen A. Respiratory and systemic monocytes, dendritic cells, and myeloid-derived suppressor cells in COVID-19: Implications for disease severity. J. Intern. Med., 2022, vol. 23, no. 10, pp. 1111. doi: 10.1186/s13075-017-1237-9</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Farina A., Rosato E., York M., Gewurz B.E., Trojanowska M., Farina G.A. Innate immune modulation induced by EBV lytic infection promotes endothelial cell inflammation and vascular injury in scleroderma. Front. Immunol., 2021, no. 12: 651013. doi: 10.3389/fimmu. 2021.651013</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Finak G., Langweiler M., Jaimes M., Malek M., Taghiyar J., Korin Y., Raddassi K., Devine L., Obermoser G., Pekalski M.L., Pontikos N., Diaz A., Heck S., Villanova F., Terrazzini N., Kern F., Qian Y., Stanton R., Wang K., Brandes A., Ramey J., Aghaeepour N., Mosmann T., Scheuermann R.H., Reed E., Palucka K., Pascual V., Blomberg B.B., Nestle F., Nussenblatt R.B., Brinkman R.R., Gottardo R., Maecker H., McCoy J.P. Standardizing Flow Cytometry Immunophenotyping Analysis from the Human Immuno Phenotyping Consortium. Sci. Rep., 2016, vol. 6: 20686. doi: 10.1038/srep20686</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Jahan H., Siddiqui N.N., Iqbal S., Basha F.Z., Shaikh S., Pizzi M., Choudhary M.I. Suppression of COX-2/PGE2 levels by carbazole-linked triazoles via modulating methylglyoxal-AGEs and glucose-AGEs — induced ROS/NF-|B signaling in monocytes. Cell. Signal, 2022, vol. 97: 110372. doi: 10.1016/j.cellsig. 2022.110372</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kabanov D.S., Grachev S.V., Prokhorenko I.R. Monoclonal antibody to CD14, TLR4, or CD11b: impact of epitope and isotype specificity on ROS generation by human granulocytes and monocytes. Oxid. Med. Cell. Longev., 2020, vol. 2020: 5708692. doi: 10.1155/2020/5708692</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kaur K., Bachus H., Lewis C., Papillion A.M., Rosenberg A.F., Ballesteros-Tato A., León B. GM-CSF production by non-classical monocytes controls antagonistic LPS-driven functions in allergic inflammation. Cell. Rep., 2021, vol. 37, no. 13: 110178. doi: 10.1016/j.celrep. 2021.110178</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Khan S., Siddique R., Hao X., Lin Y., Liu Y., Wang X., Hua L., Nabi G. The COVID-19 infection in children and its association with the immune system, prenatal stress, and neurological complications. Int. J. Biol. Sci, 2022, vol. 18, no. 2, pp. 707−716. doi: 10.7150/ijbs.66906</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kwissa M., Nakaya H.I., Onlamoon N., Wrammert J., Villinger F., Perng G.C., Yoksan S., Pattanapanyasat K., Chokephaibulkit K., Ahmed R., Pulendran B. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell. Host. Microbe., 2014, vol. 16, no. 1, pp. 115–270. doi: 10.1016/j.chom. 2014.06.001</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lazarus H.M., Pitts K., Wang T., Lee E., Buchbinder E., Dougan M., Armstrong D.G., Paine R. 3rd, Ragsdale C.E., Boyd T., Rock E.P., Gale R.P. Recombinant GM-CSF for diseases of GM-CSF insufficiency: correcting dysfunctional mononuclear phagocyte disorders. Front. Immunol., 2023, vol. 13, 1069444. doi: 10.3389/fimmu. 2022.1069444</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Li F., Piattini F., Pohlmeier L., Feng Q., Rehrauer H., Kopf M. Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection. Sci. Immunol., 2022, vol. 7, no. 73: 5761. doi: 10.1126/sciimmunol.abj5761</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lotfi N., Zhang G.X., Esmaeil N., Rostami A. Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes. Sci. Rep., 2020, vol. 10, no. 1: 1567. doi: 10.1038/s41598-020-58131-2</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Michel M., Malergue F., Ait Belkacem I., Bourgoin P., Morange P.E., Arnoux I., Miloud T., Million M., Tissot-Dupont H., Mege J.L., Vitte J., Busnel J.M. A rapid, easy, and scalable whole blood monocyte CD169 assay for outpatient screening during SARS-CoV-2 outbreak, and potentially other emerging disease outbreaks. SAGE Open Med., 2022, vol. 10, 20503121221115483. doi: 10.1177/20503121221115483</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mohamedaly S., Levy C.S., Korsholm C., Alkhani A., Rosenberg K., Ashouri J.F., Nijagal A. hepatic Ly6CLo non-classical monocytes have increased Nr4a1 (Nur77) in murine biliary atresia. J. Clin. Med., 2022, vol. 11, no. 18, pp. 5290. doi: 10.3390/jcm11185290</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Moraes-Pinto M.I., Suano-Souza F., Aranda C.S. Immune system: development and acquisition of immunological competence. J. Pediatr. (Rio J.), 2021, vol. 97, suppl. 1, pp. S59–S66. doi: 10.1016/j.jped. 2020.10.006</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Narasimhan P.B., Marcovecchio P., Hamers A.AJ., Hedrick C.C. Nonclassical monocytes in health and disease. Annu. Rev. Immunol., 2019, vol. 37, pp. 439–456. doi: 10.1146/annurev-immunol-042617-053119</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ożańska A., Szymczak D., Rybka J. Pattern of human monocyte subpopulations in health and disease. Scand. J. Immunol., 2020, vol. 92, no. 1: e12883. doi: 10.1111/sji.12883</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Páez-Guillán E.M., Campos-Franco J., Alende R., Garitaonaindía Y., González-Quintela A. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis. Lipids Health Dis., 2021, vol. 20, no. 1: 177. doi: 10.1186/s12944-021-01603-9</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Rutkowska E., Kwiecień I., Kłos K., Rzepecki P., Chciałowski A. Intermediate monocytes with PD-L1 and CD62L expression as a possible player in active SARS-CoV-2 infection. Viruses, 2022, vol. 14, no 4: 819. doi: 10.3390/v14040819</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Saxton R.A., Glassman C.R., Garcia K.C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov., 2023, vol. 22, no. 1, pp. 21–37. doi: 10.1038/s41573-022-00557-6</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Schünemann L.M., Schuberth H.J. Non-classical monocytes contribute to innate immune training in cattle. Innate Immun., 2022, vol. 28, no. 6, pp. 199–210. doi: 10.1177/ 17534259221114219</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Sebastian A., Sanju S., Jain P., Priya V.V., Varma P.K., Mony U. Non-classical monocytes and its potential in diagnosing sepsis post cardiac surgery. Int. Immunopharmacol., 2021, vol. 99: 108037. doi: 10.1016/j.intimp. 2021.108037</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Shahzad F., Bashir N., Ali A., Jabeen S., Kashif M., Javaid K., Tahir R., Abbas A., Jahan S., Afzal N. Decreased classical monocytes and CD163 expression in TB patients: an indicator of drug resistance. Braz. J. Microbiol., 2021, vol. 52, no. 2, pp. 607–617. doi: 10.1007/s42770-021-00454-x</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Silva T., Gomes L., Jeewandara C., Ogg G.S., Malavige G.N. Dengue NS1 induces phospholipase A2 enzyme activity, prostaglandins, and inflammatory cytokines in monocytes. Antiviral. Res., 2022, vol. 202: 105312. doi: 10.1016/j.antiviral. 2022.105312</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Spiteri A.G., Ni D., Ling Z.L., Macia L., Campbell I.L., Hofer M.J., King N.J.C. PLX5622 reduces disease severity in lethal CNS infection by off-target inhibition of peripheral inflammatory monocyte production. Front. Immunol., 2022, vol. 13: 851556. doi: 10.3389/fimmu. 2022.851556</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Sullivan K., Isabel S., Khodai-Booran N., Paton T.A., Abdulnoor M., Dipchand A.I., Hébert D., Ng V.L., Allen U.D. Epstein–Barr virus latent gene EBNA-1 genetic diversity among transplant patients compared with patients with infectious mononucleosis. Clin. Transplant. 2019, vol. 33, no. 4: e13504. doi: 10.1111/ctr.13504</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Sutherland D.R., Ortiz F., Quest G., Illingworth A., Benko M., Nayyar R., Marinov I. High-sensitivity 5-, 6-, and 7-color PNH WBC assays for both Canto II and Navios platforms. Cytometry B Clin. Cytom., 2018, vol. 94, no. 1, pp. 1–15. doi: 10.1002/cyto.b.21626</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Wirthgen E., Hornschuh M., Wrobel I.M., Manteuffel C., Däbritz J. Mimicking of blood flow results in a distinct functional phenotype in human non-adherent classical monocytes. Biology (Basel), 2021, vol. 10, no. 8: 748. doi: 10.3390/ biology10080748</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Zhang L. A common mechanism links Epstein–Barr virus infections and autoimmune diseases. J. Med. Virol. 2023, vol. 95, no. 1: e28363. doi: 10.1002/jmv.28363.</mixed-citation></ref></ref-list></back></article>
